BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 34108678)

  • 1. Towards precision medicine in heart failure.
    Weldy CS; Ashley EA
    Nat Rev Cardiol; 2021 Nov; 18(11):745-762. PubMed ID: 34108678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards Precision in HF Pharmacotherapy.
    Norgard NB; Hempel C
    Curr Heart Fail Rep; 2017 Feb; 14(1):1-6. PubMed ID: 28190189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Treatment for Heart Failure.
    Lin X; Fang L
    Adv Exp Med Biol; 2020; 1177():269-295. PubMed ID: 32246448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
    Senni M; Paulus WJ; Gavazzi A; Fraser AG; Díez J; Solomon SD; Smiseth OA; Guazzi M; Lam CS; Maggioni AP; Tschöpe C; Metra M; Hummel SL; Edelmann F; Ambrosio G; Stewart Coats AJ; Filippatos GS; Gheorghiade M; Anker SD; Levy D; Pfeffer MA; Stough WG; Pieske BM
    Eur Heart J; 2014 Oct; 35(40):2797-815. PubMed ID: 25104786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients.
    Ahmad T; Lund LH; Rao P; Ghosh R; Warier P; Vaccaro B; Dahlström U; O'Connor CM; Felker GM; Desai NR
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiome-Based Management of Patients With Heart Failure: JACC Review Topic of the Week.
    Mamic P; Snyder M; Tang WHW
    J Am Coll Cardiol; 2023 May; 81(17):1729-1739. PubMed ID: 37100490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology.
    Shah SJ
    J Am Soc Echocardiogr; 2019 Nov; 32(11):1379-1395.e2. PubMed ID: 31679580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study.
    Abboud A; Nguonly A; Bean A; Brown KJ; Chen RF; Dudzinski D; Fiseha N; Joice M; Kimaiyo D; Martin M; Taylor C; Wei K; Welch M; Zlotoff DA; Januzzi JL; Gaggin HK
    Open Heart; 2021 Oct; 8(2):. PubMed ID: 34663746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Stratification Towards Precision Medicine in Heart Failure - Current Progress and Future Perspectives.
    Nagai T; Nakao M; Anzai T
    Circ J; 2021 Apr; 85(5):576-583. PubMed ID: 33658445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Polovina M; Bauersachs J; Arad M; Ben Gal T; Lund LH; Felix SB; Arbustini E; Caforio ALP; Farmakis D; Filippatos GS; Gialafos E; Kanjuh V; Krljanac G; Limongelli G; Linhart A; Lyon AR; Maksimović R; Miličić D; Milinković I; Noutsias M; Oto A; Oto Ö; Pavlović SU; Piepoli MF; Ristić AD; Rosano GMC; Seggewiss H; Ašanin M; Seferović JP; Ruschitzka F; Čelutkiene J; Jaarsma T; Mueller C; Moura B; Hill L; Volterrani M; Lopatin Y; Metra M; Backs J; Mullens W; Chioncel O; de Boer RA; Anker S; Rapezzi C; Coats AJS; Tschöpe C
    Eur J Heart Fail; 2019 May; 21(5):553-576. PubMed ID: 30989768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Role of Rare Genetic Variation in Patients With Heart Failure.
    Povysil G; Chazara O; Carss KJ; Deevi SVV; Wang Q; Armisen J; Paul DS; Granger CB; Kjekshus J; Aggarwal V; Haefliger C; Goldstein DB
    JAMA Cardiol; 2021 Apr; 6(4):379-386. PubMed ID: 33326012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing.
    El Hadidi S; Rosano G; Tamargo J; Agewall S; Drexel H; Kaski JC; Niessner A; Lewis BS; Coats AJS; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):187-210. PubMed ID: 32941594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
    Shah SJ; Kitzman DW; Borlaug BA; van Heerebeek L; Zile MR; Kass DA; Paulus WJ
    Circulation; 2016 Jul; 134(1):73-90. PubMed ID: 27358439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of heart failure.
    Lopes LR; Elliott PM
    Biochim Biophys Acta; 2013 Dec; 1832(12):2451-61. PubMed ID: 23298545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial.
    Allen LA; Venechuk G; McIlvennan CK; Page RL; Knoepke CE; Helmkamp LJ; Khazanie P; Peterson PN; Pierce K; Harger G; Thompson JS; Dow TJ; Richards L; Huang J; Strader JR; Trinkley KE; Kao DP; Magid DJ; Buttrick PM; Matlock DD
    Circulation; 2021 Feb; 143(5):427-437. PubMed ID: 33201741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tensor Factorization for Precision Medicine in Heart Failure with Preserved Ejection Fraction.
    Luo Y; Ahmad FS; Shah SJ
    J Cardiovasc Transl Res; 2017 Jun; 10(3):305-312. PubMed ID: 28116551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?
    Ameri P; Bertero E; Maack C; Teerlink JR; Rosano G; Metra M
    Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):539-546. PubMed ID: 34037742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure.
    Selvaraj S; Kelly DP; Margulies KB
    Circulation; 2020 Jun; 141(22):1800-1812. PubMed ID: 32479196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulants across the heart failure spectrum: the precision medicine era.
    Paolillo S; Ruocco G; Filardi PP; Palazzuoli A; Tocchetti CG; Nodari S; Lombardi C; Metra M; Correale M;
    Heart Fail Rev; 2022 Jan; 27(1):135-145. PubMed ID: 32583229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GRK2 inhibition in heart failure: something old, something new.
    Lymperopoulos A; Rengo G; Koch WJ
    Curr Pharm Des; 2012; 18(2):186-91. PubMed ID: 22229578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.